Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Takeda projects

393 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 9 of 9
  1. placebo

    Takeda

    Non-cancer Pain

    phase 3 small molecule terminated

    1 trial
  2. prucalopride

    Takeda

    Functional Constipation

    phase 3 small molecule completed

    1 trial
  3. rVWF

    Takeda

    Von Willebrand Disease (VWD)

    phase 3 mab completed

    1 trial
  4. rozerem

    Takeda

    Insomnia

    phase 3 small molecule completed

    1 trial
  5. teduglutide 0.05 mg/kg/d

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial
  6. trifluridine/tipiracil

    Takeda

    Metastatic Oesogastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  7. velaglucerase alfa

    Takeda

    Gaucher Disease, Type 1

    phase 3 mab completed

    1 trial
  8. vitamin D

    Takeda

    COVID-19

    phase 3 other completed

    1 trial
  9. von Willebrand factor (Recombinant)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.